CSL Of Australia Considers Doubling Seasonal Flu Vaccine Production
This article was originally published in PharmAsia News
Executive Summary
Australia's CSL is considering production of twice the seasonal influenza vaccine it had planned for the next fiscal year. The company decided on the move after U.S. pre-season orders reserved nearly all of the production originally planned. In demand is CSL's Afluria, expected to be worth $80 million in sales in the year that begins July 1. The U.S. military is expected to be a major buyer of the batch of 9 million doses exported by CSL. A market analyst said the U.S. order might be driven by the increased flu awareness brought on by the H1N1 pandemic. (Click here for more